IIHMR University records highest package this placement year

IMT News Desk
IMT News Desk
· 2 min read

The ongoing placements at the institute have already witnessed 75 per cent of the students being placed now in multiple roles across diverse organisations both nationally and internationally at noteworthy packages

IIHMR University, a leading health management research university in India, recorded phenomenal placements so far this season with the highest package of 35.62 LPA. This is the highest package beating IIHMR’s previous high of 17.22 LPA in 2022. The ongoing placements at the institute have already witnessed 75 per cent of the students being placed till now in multiple roles across diverse organisations both nationally and internationally at noteworthy packages.

Dr PR Sodani, President, IIHMR University shared, “We are delighted to receive excellent placement response from the recruiters on campus this year. Packages in the healthcare industry are witnessing a spike secondary to the global growing emphasis on bolstering healthcare infrastructure. I want to congratulate the students on getting placed and wish them well for their future as they continue to build their success stories.”

Remarkable to note is that according to a collaborative study by Pristyn Care and Indeed, job postings for healthcare professionals increased by 22.4 per cent between January 2021 and January 2023, indicating a growing demand for these professionals in India.

According to the placement officials at IIHMR University, the total number of recruiters has gone up to 60+, with HJ Hospital, IPE Global, Nuva Bupa Health Insurance Ltd., Tata AIG, Lupin, Deloitte, PWC, E&Y, Infosys, and Fortis Hospital to name a few from a long list. The sector-wise placement data revealed Hospitals to be the highest recruiters at 30 per cent followed by Consultancy, Pharmaceutical, and Health IT at 15 per cent, 12 per cent, 11 per cent and 11 per cent respectively. 

The current year registered a massive rise of 220 per cent in the number of students securing a package of 13 lakh and above. The 10 lakhs plus CTC range registered an increase of 82 per cent in students in 2024. The 8 LPA plus packages witnessed a commendable rise of 115 per cent as compared to 2021-23.

 

 

Read Next

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet
News
April 16, 2026

‘One Nation, One Emergency Helpline’ Proposal for Stroke Care Gains Momentum at FICCI Meet

India’s stroke crisis demands urgent action, and the Indian Stroke Association (ISA) is leading the charge with a bold proposal for a unified national helpline. The ISA presented a comprehensive plan to strengthen stroke care delivery at a FICCI-hosted meeting attended by policymakers, healthcare leaders, and clinical experts. The plenary session, “Strengthening Stroke Care Delivery,” […]
Article by: IMT News Desk
Ivory raises fresh capital to strengthen deep tech offerings
News
April 16, 2026

Ivory raises fresh capital to strengthen deep tech offerings

Ivory, a brain health platform focused on early cognitive screening, has raised $1M in fresh funding, onboarding new investors to deepen its product, clinical and IP capabilities. The round saw participation from Draper Associates, a global venture capital firm with a strong focus on biotech and healthtech, along with SAGE Venture Fund, an AIF fund launched […]
Article by: IMT News Desk
Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition
News
April 16, 2026

Rubicon Research Enters Indian CNS Formulations Market with Strategic Acquisition

Rubicon Research Limited today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited from its current shareholders. With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulation companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 […]
Article by: IMT News Desk
MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide
News
April 16, 2026

MSN Laboratories Launches ‘SEMABEST, the First Integrated Made-in-India Semaglutide

MSN Laboratories has launched SEMABEST, its semaglutide brand, in the Indian market following approval from the Central Drugs Standard Control Organisation (CDSCO). SEMABEST is priced at nearly 50% lower than the innovator drug, significantly improving affordability and patient access. The therapy is available as a pre-filled pen for subcutaneous administration. In this evolving landscape, SEMABEST […]
Article by: IMT News Desk